KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to 40.91%.

  • Rigel Pharmaceuticals' EBITDA Margin rose 155000.0% to 40.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.17%, marking a year-over-year increase of 361400.0%. This contributed to the annual value of 13.49% for FY2024, which is 310300.0% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported EBITDA Margin of 40.91% as of Q3 2025, which was up 155000.0% from 60.09% recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year EBITDA Margin high stood at 60.09% for Q2 2025, and its period low was 156.92% during Q1 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' median EBITDA Margin value was 15.87% (recorded in 2023), while the average stood at 20.8%.
  • Examining YoY changes over the last 5 years, Rigel Pharmaceuticals' EBITDA Margin showed a top increase of 1090000bps in 2022 and a maximum decrease of -2084600bps in 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' EBITDA Margin (Quarter) stood at 104.94% in 2021, then skyrocketed by 104bps to 4.05% in 2022, then skyrocketed by 35bps to 5.49% in 2023, then surged by 426bps to 28.92% in 2024, then soared by 41bps to 40.91% in 2025.
  • Its EBITDA Margin stands at 40.91% for Q3 2025, versus 60.09% for Q2 2025 and 23.95% for Q1 2025.